| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/05/2006 | WO2005027874A3 Solid or semi-solid therapeutic formulations |
| 01/05/2006 | WO2005000357A3 Chemical combination and method for increasing delivery of coenzyme q 10 |
| 01/05/2006 | WO2004093813A3 Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders |
| 01/05/2006 | WO2003102153A3 Cell migration inhibiting compositions and methods and compositions for treating cancer |
| 01/05/2006 | WO2003087338A3 Her-2 receptor tyrosine kinase molecules and uses thereof |
| 01/05/2006 | WO2003016493A3 Transporters and ion channels |
| 01/05/2006 | US20060004104 Use of 5-alkyl substituted 2-arylaminophenylacetic acid derivatives as selective cyclooxygenase-2 inhibitors in the treatment of cancer pain, especially bone cancer pain; for example, 5-methyl-2-(2'-chloro-6'-fluoroanilino)-phenylacetic acid |
| 01/05/2006 | US20060004077 Inhibiting class II MHC-mediated activation of T cells; peptidomimetics of given sequence which include a Gpg (guanylpiperidyl glycine) unit; rheumatoid arthritis and/or multiple sclerosis; e.g. Ac-Cha-Gpg-Tic-Nle-NHCH2CH2Ph (Cha=cyclohexylalanine, Tic=3-carboxyisoquinoline, Nle=norleucine) |
| 01/05/2006 | US20060004073 Compounds, compositions, and methods |
| 01/05/2006 | US20060004062 Compounds for inhibiting insulin secretion and methods related thereto |
| 01/05/2006 | US20060004056 Di-aryl-substituted-ethan pyridone pde4 inhibitors |
| 01/05/2006 | US20060004054 Administering 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline before or at the time angioplasty, coronary by-pass grafting or stent implantation |
| 01/05/2006 | US20060004040 Method for the prevention and/or treatment of atherosclerosis |
| 01/05/2006 | US20060003996 Intralesional treatment of psoriasis |
| 01/05/2006 | US20060003992 New drug combinations |
| 01/05/2006 | US20060003989 Compositions and methods using acetylcholinesterase (ACE) inhibitors to treat central nervous system (CNS) disorders in mammals |
| 01/05/2006 | US20060003984 Monobactam compositions and methods of use thereof |
| 01/05/2006 | US20060003981 Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders |
| 01/05/2006 | US20060003975 Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor |
| 01/05/2006 | US20060003955 Immunostimulatory nucleic acid molecules |
| 01/05/2006 | US20060003942 Combinations for HCV treatment |
| 01/05/2006 | US20060003933 Compositions and methods for treatment of neovascular diseases |
| 01/05/2006 | US20060003932 Method for promoting neovascularization |
| 01/05/2006 | US20060003928 Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| 01/05/2006 | US20060003927 Modulation of immune function |
| 01/05/2006 | US20060003410 Oxidoreductase for use in identifying modulators for prevention and treatment of diabetes, obesity, dyslipidemia, coronary heart, inflammatory and cancer disorders |
| 01/05/2006 | US20060003379 Smad6 and uses thereof |
| 01/05/2006 | US20060003020 Anti-metastatic ability of mibefradil and gadolinium |
| 01/05/2006 | US20060003012 Preparation of submicron solid particle suspensions by sonication of multiphase systems |
| 01/05/2006 | US20060003009 Slow release protein polymers |
| 01/05/2006 | US20060002983 Muscle building preparation |
| 01/05/2006 | US20060002954 Composition trapping radicals in organism |
| 01/05/2006 | US20060002911 Association between a ppar ligand and an antioxidant agent and use thereof for treating obesity |
| 01/05/2006 | US20060002910 Agent for the anti-adhesion of skin pathogenic flora |
| 01/05/2006 | US20060002909 Microorganism separated from Kefir grains, a microorganism culture obtained by culturing said microorganism or microorganisms including it, and a product using such microorganisms or microorganism cultures |
| 01/05/2006 | US20060002908 Bifidobacterium in the treatment of inflammatory disease |
| 01/05/2006 | US20060002907 Method of improving immune function in mamals using lactobacillus reuteri strains |
| 01/05/2006 | US20060002903 comprises anti-inflammatory conformal barriers with controllable permeability properties that can be applied to living cells prior to transplant, and methods for coating living cells with conformal barriers |
| 01/05/2006 | US20060002902 System for providing implant compatibility with recipient |
| 01/05/2006 | US20060002901 Composition containing eosinophil cationic protein |
| 01/05/2006 | US20060002900 Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
| 01/05/2006 | US20060002899 Generation of dendritic cells from cd34+precursors |
| 01/05/2006 | US20060002893 Targeted adenovirus vectors for delivery of heterologous genes |
| 01/05/2006 | US20060002861 Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothiate androstanes with a muscarinic receptor antagonist |
| 01/05/2006 | US20060002858 Concentrated X-ray contrast media can act as universal antigens and can inhibit or prevent allergic reactions |
| 01/05/2006 | DE102004029325A1 Use of a medicament, comprising cholinesterase inhibitor (e.g. donepezil), for the treatment of behavior disturbances and/or disturbances of cognitive functions caused due to the fetal alcohol syndrome |
| 01/05/2006 | DE102004028899A1 Mittel zur Steigerung der Aktivität der sekretorischen Phospholipase A2-IIA Means for enhancing the activity of the secretory phospholipase A2-IIA |
| 01/05/2006 | CA2612006A1 Phospholipid compositions and methods for their preparation and use |
| 01/05/2006 | CA2589563A1 Method of screening compound directly activating glycogen synthase |
| 01/05/2006 | CA2588571A1 Insulin secretagogue drugs |
| 01/05/2006 | CA2579716A1 Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and at1-receptor antagonists |
| 01/05/2006 | CA2571611A1 Cell-based therapies for ischemia |
| 01/05/2006 | CA2571584A1 Method of treating ileus by pharmacological activation of cholinergic receptors |
| 01/05/2006 | CA2571449A1 Compositions comprising strontium and vitamin d and uses thereof |
| 01/05/2006 | CA2571444A1 Compositions for topical treatment |
| 01/05/2006 | CA2571421A1 Compounds for immunopotentiation |
| 01/04/2006 | EP1612281A2 Methods for assessing patients with acute myeloid leukemia |
| 01/04/2006 | EP1612272A2 Novel antiangiogenic peptides, polynucleotides encoding same and methods for inhibiting angiogenesis |
| 01/04/2006 | EP1612266A2 Prostaglandin reductase |
| 01/04/2006 | EP1612222A2 Olfactory and pheromones G-protein coupled receptors |
| 01/04/2006 | EP1611902A1 Preventive and/or therapeutic agent for neuropathic pain |
| 01/04/2006 | EP1611901A1 Preventive or remedy for teeth grinding |
| 01/04/2006 | EP1611897A2 Whole or disrupted insect cells as adjuvant for antigens |
| 01/04/2006 | EP1611887A2 Modulation of peroxisome proliferator-activated receptors |
| 01/04/2006 | EP1611886A2 Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders |
| 01/04/2006 | EP1611885A1 Use of an inducing agent for the treatment of blood, viral and cellular disorders |
| 01/04/2006 | EP1611231A2 Rna interference compositions and methods |
| 01/04/2006 | EP1611130A2 Reverse-turn mimetics and method relating thereto |
| 01/04/2006 | EP1611095A2 A method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith |
| 01/04/2006 | EP1611088A2 Hydroxamates as therapeutic agents |
| 01/04/2006 | EP1610812A1 Pharmaceutical preparations comprising acid-stabilised insulin |
| 01/04/2006 | EP1610806A2 Method of treating cancer with azaspirane compositions |
| 01/04/2006 | EP1610797A1 Antiviral combination of nevirapine and a further antiretroviral compound |
| 01/04/2006 | EP1610788A1 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| 01/04/2006 | EP1610787A1 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| 01/04/2006 | EP1610782A1 Antiviral combination of a dipyridodiazepinone and a further antiretroviral compound |
| 01/04/2006 | EP1610781A1 Antiviral combination of tipranavir and a further antiretroviral compound |
| 01/04/2006 | EP1610773A2 Use of compounds for the prevention of drug-induced cell toxicity |
| 01/04/2006 | EP1397153A4 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 01/04/2006 | EP1357941B1 Therapeutical use of anti-mag antibody for the treatment of ischemic stroke |
| 01/04/2006 | EP1311677B1 Regulation of human p2y1-like g protein-coupled receptor |
| 01/04/2006 | EP1242403B1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 01/04/2006 | EP1237553B1 The combination of a serotonin reuptake inhibitor and a 5-ht 2c? antagonist, inverse agonist or partial agonist |
| 01/04/2006 | EP1223950B1 Ribozyme therapy for the treatment of proliferative eye diseases |
| 01/04/2006 | EP1212000B1 System for controlling body temperature while reducing shivering |
| 01/04/2006 | EP1146881B1 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin |
| 01/04/2006 | EP1131051B1 Pressurised metered dose inhalers (mdi) |
| 01/04/2006 | EP1128844B1 Botulinum toxins for enhancing wound healing |
| 01/04/2006 | EP1067945B1 Methods for reducing cholesterol using bacillus coagulans spores, systems and compositions |
| 01/04/2006 | EP1044008B1 Use of aliphatic polyamines for reducing oxalate |
| 01/04/2006 | EP0820286B1 Tetrandrine for the treatment for ocular inflammation |
| 01/04/2006 | CN1717253A Solid preparation |
| 01/04/2006 | CN1717252A Preparation containing basic drug |
| 01/04/2006 | CN1717245A Medicinal composition |
| 01/04/2006 | CN1717230A Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor |
| 01/04/2006 | CN1717228A Pharmaceutical composition comprising a LTB4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 01/04/2006 | CN1717224A Therapeutic compositions |
| 01/04/2006 | CN1714867A Triacetin as a transdermal penetration enhancer |
| 01/04/2006 | CN1714866A A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes |
| 01/04/2006 | CN1714783A Implantable particles for tissue bulking and the treatment |